ClinicalTrials.gg
CompletedNCT06176365SYNCHRONIZE™JPUpdated Apr 30, 2026

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

A Phase 3 interventional study of Survodutide and Placebo matching survodutide in Obesity, sponsored by Boehringer Ingelheim. Completed at 28 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.

Enrollment
9th of 22
274 · median 121
Started
2024
with 7 others
Phase 3
9 of 22
3 open now
Registered
9th of 22
by date
Lead sponsor
22 of 22
Boehringer Ingelheim

Among the 22 studies testing survodutide in Obesity, this one is the 9th largest by enrollment, is one of 8 that started in 2024, is one of 9 in phase 3, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About survodutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing survodutide in Obesity, or all of them as a file.
02

Study summary

This study is open to adults who are at least 18 years old and have

  • a body mass index (BMI) of 35 kg/m² or more and at least one health problem related to their weight, or
  • a BMI of 27 kg/m² or more and at least two health problems related to their weight.

People who have either type 2 diabetes, high blood pressure, or increased blood lipids can take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate.

The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with obesity disease to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine.

Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.

Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff.

The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18 years at the time of signing
  2. (BMI)

    • ≥35 kg/m² at screening with the presence of at least one obesity-related comorbidities (treated or untreated) according to the Japan Society for the Study of Obesity (JASSO) guideline OR
    • BMI ≥27 kg/m² at screening with the presence of at least two obesity-related comorbidities (treated or untreated) according to the JASSO guideline For all trial patients, at least one co-morbidity should be the following (i)-(iii).

      i. Type 2 diabetes mellitus (T2DM)

      • Diagnosed with T2DM (defined as Glycosylated (HbA1c) ≥6.5% [≥48 mmol/mol]) at least 180 days prior to screening
      • HbA1c ≥6.5% (48 mmol/mol) and \<10% (86 mmol/mol) as measured by the central laboratory at screening
      • Currently treated with either: diet and exercise alone or stable treatment (for at least 3 months prior to screening) with metformin, SGLT-2i, acarbose, sulfonylurea, or glitazone as single agent therapy, or up to 3 antihyperglycaemia medications (metformin, SGLT-2i, acarbose, sulfonylurea, or glitazone) according to local label ii. Hypertension iii. Dyslipidaemia
  3. History of at least one self-reported unsuccessful dietary effort to lose body weight
  4. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
  5. Woman of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use will be provided in the patient information.
  6. In the investigator's opinion, patients are well-motivated, capable, and willing to:

    • Learn how to self-inject the medicinal product (IMP), as required for this protocol (persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the IMP) OR
    • Inject the IMP or accept injection from a designated person
    • Follow study procedures for the duration of the study, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and exercise and exercise plan), maintain a diary, and complete required questionnaires, and handle the IMP as described in the instructions for use (IFU)

Exclusion criteria

Exclusion criteria:

Obesity:

  1. Body weight change (self-reported) >5% within 3 months before screening
  2. Treatment with any medication for the indication obesity within 3 months before screening
  3. Previous or planned (during the trial period) treatment for obesity with surgery or a weight loss device, or prior surgery of the gastrointestinal (GI) tract that could interfere with body weight The following are allowed: (1) liposuction and/or abdominoplasty, if performed >1 year before screening, (2) lap banding, if the band has been removed >1 year before screening, (3) intragastric balloon, if the balloon has been removed >1 year before screening, (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed >1 year before screening, (5) appendectomy, (6) simple hernia repair, or (7) cholecystectomy.
  4. Have obesity induced by other endocrinologic disorders (i.e. Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (i.e. melanocortin 4 receptor deficiency, leptin deficiency, or Prader Willi Syndrome)

    Glycaemia:

    For trial patients without T2DM:

  5. History of T1DM or T2DM or treatment with glucose lowering agent started within 3 months before screening

    For trial patients with T2DM:

  6. History of T1DM
  7. Treatment with any medication for the indication of T2DM other than stated in the inclusion criteria within 3 months before screening (i.e. insulin, amylin analogues, GLP-1R agonists, GLP-1R agonist/insulin/GIP combinations, and DPP-4i)
  8. New initiation of any other glucose-lowering drug within 3 months prior to screening for this trial

Further exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
274 participants (actual)

Study arms

  • Experimental
    Survodutide - 3.6 mg

    Drug: Survodutide

  • Experimental
    Survodutide - 6.0 mg

    Drug: Survodutide

  • Placebo comparator
    Placebo group

    Drug: Placebo matching survodutide

Interventions

  • once weekly subcutaneous injection

    Also known as: BI 456906

  • DrugPlacebo matching survodutide

    once weekly subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline to Week 76

    Time frame: at baseline, at week 76

  2. Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76

    Time frame: at baseline, at week 76

Secondary outcomes

  1. Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76

    Time frame: at baseline, at week 76

  2. Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76

    Time frame: at baseline, at week 76

  3. Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76

    Time frame: at baseline, at week 76

  4. Absolute change from baseline to Week 76 in body weight (kg)

    Time frame: at baseline, at week 76

  5. Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m²)

    Time frame: at baseline, at week 76

  6. Absolute change from baseline to Week 76 in waist circumference measured at umbilical level (cm)

    Time frame: at baseline, at week 76

  7. Absolute change from baseline to Week 76 in waist circumference measured at midway between the lower rib margin and the iliac crest (cm)

    Time frame: at baseline, at week 76

  8. Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)

    Time frame: at baseline, at week 76

  9. Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)

    Time frame: at baseline, at week 76

  10. Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of the Eating Behaviour Patient reported outcome (PRO)

    The "Capacity to Resist domain score" of the Eating Behaviour Patient reported outcome (PRO) (units on a scale) will be derived as the sum of items in the domain (possible responses being 0="Not at all", 1="A little", 2="Moderately", 3="A lot", 4="Extremely"). The domain score is ranging between 0 and 24 and a higher score indicates a lower capacity to resist.

    Time frame: at baseline, at week 76

  11. Absolute change from baseline to Week 76 in Eating Behaviour PRO total score

    The Eating Behaviour PRO total score (units on a scale) will be derived from the "Desire to Eat" and "Capacity to Resist" domain as the sum of all items (possible responses being 0="Not at all", 1="A little", 2="Moderately", 3="A lot", 4="Extremely"). Each domain consists of 6 items. The score is ranging between 0 and 48 and a higher score indicates a worse eating behaviour (greater desire to eat and/or lower capacity to resist).

    Time frame: at baseline, at week 76

  12. Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)

    Time frame: at baseline, at week 76

  13. Absolute change from baseline to Week 76 in HbA1c (mmol/mol)

    Time frame: at baseline, at week 76

  14. Absolute change from baseline to Week 76 in fasting plasma glucose (FPG) (mg/dL)

    Time frame: at baseline, at week 76

  15. Absolute change from baseline to Week 76 in fasting plasma insulin (FPI) (mIU/L)

    Time frame: at baseline, at week 76

  16. Absolute change from baseline to Week 76 in total cholesterol (mg/dL)

    Time frame: at baseline, at week 76

  17. Absolute change from baseline to Week 76 in high density lipoprotein (HDL) (mg/dL)

    Time frame: at baseline, at week 76

  18. Absolute change from baseline to Week 76 in low density lipoprotein (LDL) (mg/dL)

    Time frame: at baseline, at week 76

  19. Absolute change from baseline to Week 76 in very-low-density lipoprotein (VLDL) (mg/dL)

    Time frame: at baseline, at week 76

  20. Absolute change from baseline to Week 76 in triglycerides (mg/dL)

    Time frame: at baseline, at week 76

  21. Absolute change from baseline to Week 76 in free fatty acids (mg/dL)

    Time frame: at baseline, at week 76

  22. Absolute change from baseline to Week 76 in alanine aminotransferase (ALT) (U/L)

    Time frame: at baseline, at week 76

  23. Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L)

    Time frame: at baseline, at week 76

  24. Relative change from baseline to Week 76 in liver fat content (%), assessed by Magnetic resonance imaging proton density fat fraction (MRI-PDFF)

    Time frame: at baseline, at week 76

  25. Absolute change from baseline to Week 76 in total fat mass (percentage [%]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

  26. Absolute change from baseline to Week 76 in total fat mass (volume [L]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

  27. Absolute change from baseline to Week 76 in lean body mass (percentage [%]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

  28. Absolute change from baseline to Week 76 in lean body mass (volume [L]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

  29. Absolute change from baseline to Week 76 in visceral fat mass (percentage [%]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

  30. Absolute change from baseline to Week 76 in visceral fat mass (volume [L]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

  31. Absolute change from baseline to Week 76 in contractile thigh muscle volume (percentage [%]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

  32. Absolute change from baseline to Week 76 in contractile thigh muscle volume (volume [L]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

  33. Absolute change from baseline to Week 76 in sub-cutaneous fat volume (volume [L]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

  34. Absolute change from baseline to Week 76 in sub-cutaneous fat volume (percentage [%]) assessed by MRI for body composition

    Time frame: at baseline, at week 76

07

Study locations

28 sites
  • Hosokawa Surgery Clinic
    Aichi, Nagoya, 453-0812, Japan
  • Nagoya City University Hospital
    Aichi, Nagoya, 467-8602, Japan
  • Chiba University Hospital
    Chiba, Chiba, 260-8677, Japan
  • Gifu University Hospital
    Gifu, Gifu, 501-1194, Japan
  • Jiyugaoka Yamada Clinic
    Hokkaido, Obihiro, 080-0848, Japan
  • Yamasaki Family Clinic
    Hyogo, Amagasaki, 660-0861, Japan
  • Kobe University Hospital
    Hyogo, Kobe, 650-0017, Japan
  • Motomachi Takatsuka Naika Clinic
    Kanagawa, Yokohama, 231-0023, Japan
  • Morinagaueno Clinic
    Kumamoto, Kumamoto, 860-0863, Japan
  • Yoshimura Clinic
    Kumamoto, Kumamoto, 861-8039, Japan
  • Medical Corporation KEISEIKAI Kajiyama Clinic
    Kyoto, Kyoto, 600-8898, Japan
  • Ijinkai Takeda General Hospital
    Kyoto, Kyoto, 601-1495, Japan
  • Osaka Metropolitan University Hospital
    Osaka, Osaka, 545-8586, Japan
  • OCROM Clinic
    Osaka, Suita, 565-0853, Japan
  • Saino Clinic
    Saitama, Tokorozawa, 359-1141, Japan
  • Dojinkinenkai Meiwa Hospital
    Tokyo, Chiyoda-ku, 101-0041, Japan
  • Suidoubashi Medical Clinic
    Tokyo, Chiyoda-ku, 101-0065, Japan
  • Tokyo-Eki Center-building Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Tokyo Center Clinic
    Tokyo, Chuo-ku, 103-0028, Japan
  • Fukuwa Clinic
    Tokyo, Chuo-ku, 104-0031, Japan
  • Tokyo Asbo Clinic
    Tokyo, Chuo-ku, 104-0031, Japan
  • New Medical Research System Clinic
    Tokyo, Hachioji, 192-0046, Japan
  • Shimamura Kinen Hospital
    Tokyo, Nerima-ku, 177-0051, Japan
  • Clinical Research Hospital Tokyo
    Tokyo, Shinjuku-ku, 160-0004, Japan
  • HS Clinic
    Tokyo, Shinjuku-ku, 169-0072, Japan
  • ToCROM Clinic
    Tokyo, Shinjyuku-ku, 160-0008, Japan
  • Shinei Medical Healthcare Clinic
    Tokyo, Suginami-ku, 166-0003, Japan
  • Ikebukuro Metropolitan Clinic
    Tokyo, Toshima-ku, 171-0021, Japan
08

References and documents

Publications

  • Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, Inoue T, Borowska L, Brueckmann M, Ogawa W; SYNCHRONIZE-JP Trial Investigators. Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial. Diabetes Obes Metab. 2026 Aug;28(8):6595-6606. doi: 10.1111/dom.70862. Epub 2026 May 31. PubMed 42219222 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Dec 2025, 22 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 22 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Dec 19, 2023
StartActual
Jan 16, 2024
Primary completionActual
Dec 3, 2025
CompletionActual
Dec 3, 2025
Results delay requested
Apr 23, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06176365
Responsible party
Sponsor
First posted
Dec 19, 2023
Start date
Jan 16, 2024
Primary completion
Dec 3, 2025
Completion
Dec 3, 2025
Last update
Apr 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion